1. Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty.
- Author
-
Hsieh, Bing‐Han, Kuo, Yu‐Chun, Yong, Su‐Boon, Tien, Hui‐Chi, Hsu, Chun‐chieh, Hsu, Che‐Lun, Tsou, Yung‐An, Lin, Chia‐Der, Tai, Chih‐Jaan, Wang, Jiu‐Yao, and Shih, Liang‐Chun
- Abstract
Background: The efficacy of adjuvant sublingual immunotherapy (SLIT) in correcting structural problems in patients with allergic rhinitis (AR) caused by mite who have undergone septomeatoplasty (SMP) has not been studied. Methods: This non‐randomized controlled study recruited patients with AR (caused by mite) and concurrent septal deviation and inferior turbinate hypertrophy, at a tertiary hospital in Taiwan. SMP was performed on all patients as a surgical intervention. The patients were then divided into two groups: the control group, which underwent surgery only, and the experimental group, which received SLIT as an adjuvant treatment. Demographic data and rhinitis control assessment test (RCAT) results were analyzed. Results: A total of 96 patients were enrolled in the study (SMP + SLIT group, n = 52; SMP only group, n = 44). No significant differences were observed in any of the variables between the two groups before and one month after surgery. However, during evaluations at the third and sixth month, the SMP + SLIT group showed significant improvement in the total RCAT scores compared to the SMP only group (28.6 ± 1.56 vs. 24.5 ± 3.66, p < 0.001; 27.1 ± 2.87 vs. 19.9 ± 5.56, p < 0.001). In addition, significantly better control of all RCAT sub‐categories was observed in the SMP + SLIT group at the third and sixth month evaluations. Conclusions: SLIT may serve as an ideal adjuvant therapy after SMP in patients with AR. Level of Evidence: 3 Laryngoscope, 134:3073–3079, 2024 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF